新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 产品 » FDA 批准Botox治疗膀胱过度活动症

FDA 批准Botox治疗膀胱过度活动症

来源:生物谷 2013-01-21 09:16

1月18日FDA批准Botox (onabotulinumtoxinA)新的适用症,用于治疗不能正常使用anticholinergics的膀胱过度活动症的成人患者。

膀胱过动症是一种以尿急症状为特征的征候群,常伴有尿频和夜尿症状,可伴或不伴有急迫性尿失禁;尿动力学上可表现为逼尿肌过度活动,也可为其它形式的尿道-膀胱功能障碍。

当Botox注入膀胱肌肉,它会使膀胱放松,增加膀胱的容量和减少集尿失禁。膀胱注射Botox时采用膀胱镜检查,使医生可视化膀胱内部。

Botox 由Allergan生产。(生物谷Bioon.com)

英文报道:

FDA approves Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

Overactive bladder is a condition in which the bladder squeezes too often or squeezes without warning. Symptoms include leaking urine (urinary incontinence), feeling the sudden and urgent need to urinate, and frequent urination.

When Botox is injected into the bladder muscle, it causes the bladder to relax, increasing the bladder’s storage capacity and reducing episodes of urinary incontinence. Injecting the bladder with Botox is performed using cystoscopy, a procedure that allows a doctor to visualize the interior of the bladder while Botox is being injected.

“Clinical studies have demonstrated Botox’s ability to significantly reduce the frequency of urinary incontinence,” said Hylton V. Joffe, M.D., director of the Division of Reproductive and Urologic Products in FDA’s Center for Drug Evaluation and Research. “Today’s approval provides an important additional treatment option for patients with overactive bladder, a condition that affects an estimated 33 million men and women in the United States.”

Botox’s safety and effectiveness for this new indication were established in two clinical trials of 1,105 patients with symptoms of overactive bladder. Patients were randomly assigned to receive injections of 100 units of Botox (20 injections of 5 units each) or placebo.

Results after 12 weeks showed that patients treated with Botox experienced urinary incontinence an average of 1.6 to 1.9 times less per day than patients treated with placebo. Botox-treated patients also needed to urinate on average 1.0 to 1.7 times less per day and expelled an average of about 30 milliliters more urine than those treated with placebo.

Treatment with Botox can be repeated when the benefits from the previous treatment have decreased, but there should be at least 12 weeks between treatments.

Common side effects reported during clinical trials included urinary tract infections, painful urination, and incomplete emptying of the bladder (urinary retention). Patients who develop urinary retention may need to use a catheter until the urinary retention resolves. Patients being treated for overactive bladder with Botox should not have a urinary tract infection and should take antibiotics before, during, and for a few days after Botox treatment to lower the chance of developing an infection from the procedure.

Botox is manufactured by Allergan Inc. based in Irvine, Calif.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库